Zobrazit v EDS

Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: An EAU Guidelines Update: An EAU Guidelines Update

Uloženo v:
Podrobná bibliografie
Název: Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: An EAU Guidelines Update: An EAU Guidelines Update
Autoři: Skolarikos, Andreas, Somani, Bhaskar, Neisius, Andreas, Jung, Helene, Petřík, Alec, Tailly, Thomas, Davis, Niall, Tzelves, Lazaros, Geraghty, Rob, Lombardo, Riccardo, Bezuidenhout, Carla, Gambaro, Giovanni
Zdroj: European Urology. 86:343-363
Informace o vydavateli: Elsevier BV, 2024.
Rok vydání: 2024
Témata: Follow-up, Prevention, Metabolic evaluation, Urinary Calculi/prevention & control, Risk Assessment, Treatment, Secondary Prevention/methods, Urolithiasis, Recurrence, Risk Factors, Practice Guidelines as Topic, Secondary Prevention, Humans, Urinary Calculi
Popis: The aim of this review was to define patients who are at high risk of recurrence of urolithiasis, to delineate diagnostic and therapeutic algorithms for each type of stone, and to clarify general guidelines and recommendations for prevention of recurrence.A professional research librarian carried out literature searches for all sections of the urolithiasis guidelines, covering the timeframe between 1976 and June 2023.For every patient with urolithiasis, an attempt should be made to analyse the stone. Patients should be given general instructions on how to prevent recurrence, including adequate fluid and calcium intake, and low consumption of sodium and protein. Identifying and correcting the causative factors is a cornerstone in preventing the recurrence of urolithiasis. Diagnostic and therapeutic algorithms by stone composition are available. Every patient should undergo baseline metabolic screening, while patients with calcium stones, who are at high risk of relapse and complications, should undergo extensive metabolic screening with two 24-h urine collections and should receive targeted therapy. Patients with uric acid, infection, or cystine stones are at high risk of relapse. All patients at high risk of recurrence should be closely monitored, especially those not complying with therapy in the long term.Metabolic stone evaluation and patient follow-up are highly recommended to prevent urolithiasis recurrence.
Druh dokumentu: Article
Jazyk: English
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2024.05.029
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39069389
https://pergamos.lib.uoa.gr/uoa/dl/object/3491657
Rights: Elsevier TDM
Přístupové číslo: edsair.doi.dedup.....d27ac0fa1ac7d9117896f9806339906a
Databáze: OpenAIRE
Popis
Abstrakt:The aim of this review was to define patients who are at high risk of recurrence of urolithiasis, to delineate diagnostic and therapeutic algorithms for each type of stone, and to clarify general guidelines and recommendations for prevention of recurrence.A professional research librarian carried out literature searches for all sections of the urolithiasis guidelines, covering the timeframe between 1976 and June 2023.For every patient with urolithiasis, an attempt should be made to analyse the stone. Patients should be given general instructions on how to prevent recurrence, including adequate fluid and calcium intake, and low consumption of sodium and protein. Identifying and correcting the causative factors is a cornerstone in preventing the recurrence of urolithiasis. Diagnostic and therapeutic algorithms by stone composition are available. Every patient should undergo baseline metabolic screening, while patients with calcium stones, who are at high risk of relapse and complications, should undergo extensive metabolic screening with two 24-h urine collections and should receive targeted therapy. Patients with uric acid, infection, or cystine stones are at high risk of relapse. All patients at high risk of recurrence should be closely monitored, especially those not complying with therapy in the long term.Metabolic stone evaluation and patient follow-up are highly recommended to prevent urolithiasis recurrence.
ISSN:03022838
DOI:10.1016/j.eururo.2024.05.029